US equities
|
NVDA
$150.96
▼-2.89%
MU
$705.27
▼-1.00%
AMD
$530.14
▲+5.31%
SPCX
$143.50
▲+1.27%
AAPL
$352.45
▲+0.15%
MSFT
$508.29
▲+0.40%
AMZN
$267.74
▲+3.82%
TSLA
$383.72
▲+0.95%
NVDA
$150.96
▼-2.89%
MU
$705.27
▼-1.00%
AMD
$530.14
▲+5.31%
SPCX
$143.50
▲+1.27%
AAPL
$352.45
▲+0.15%
MSFT
$508.29
▲+0.40%
AMZN
$267.74
▲+3.82%
TSLA
$383.72
▲+0.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Helus Pharma Inc. - Common Stock
(NQ:
HELP
)
6.890
-0.310 (-4.31%)
Delayed Quote
Updated: 4:00 PM EST, Nov 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Helus Pharma Inc. - Common Stock
< Previous
1
2
3
4
Next >
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise
↗
February 20, 2026
Via
MarketBeat
HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’
↗
February 17, 2026
The study showed statistically significant and clinically meaningful reductions in depressive symptoms at two weeks in participants treated with SPL026 compared with placebo, the company said.
Via
Stocktwits
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
February 17, 2026
Via
Investor Brand Network
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
February 17, 2026
From
Helus Pharma
Via
GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Q3 2025 Results, Advances Phase 3 and Phase 2 Programs
February 13, 2026
Via
Investor Brand Network
Topics
Intellectual Property
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
February 13, 2026
From
Helus Pharma
Via
GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Michael Cola as Chief Executive Officer
February 10, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
February 10, 2026
EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
February 10, 2026
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior...
Via
FinancialNewsMedia
Topics
Intellectual Property
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
February 10, 2026
From
Helus Pharma
Via
GlobeNewswire
< Previous
1
2
3
4
Next >